Leverage our expansive capabilities for even greater efficiency
We’re here to empower breakthroughs
We offer a comprehensive suite of capabilities, services, and resources designed to help researchers accelerate cancer drug development to get more precise, effective, and individualized treatment options to cancer patients faster.
We offer a comprehensive suite of capabilities, services, and resources designed to help researchers accelerate cancer drug development to get more precise, effective, and individualized treatment options to cancer patients faster.
We have deep ex vivo 3D cell culture expertise
Human cell sources:
Available readouts:
Experience in multiple therapeutic mechanisms:
- Resected primary tumor tissue
- Biopsies
- Ascites
- Blood
- Excised PDX tumors
- Cell lines
- Organoids
Kiyatec has established strong relationships >10 years for sourcing continuous tissue and cell samples
- Histology
- Flow cytometry
- Cell sorting
- PCR
- Luminex
- Microarray
- High-throughput fluorescent microscopy
- Multiphoton and confocal microscopy
- Sequencing resources
- Chemotherapy
- Targeted agents
- Monoclonal Abs
- ADCs
- Checkpoint inhibitors
- Bispecifics
- CAR-Ts and other cell therapies
Proper specimen transport is critical for accelerating discoveries
We follow proprietary specimen transport protocols for both global and US shipping, which are critically important for several reasons.
We follow proprietary specimen transport protocols for both global and US shipping, which are critically important for several reasons.
Maintaining sample integrity: Proper specimen transport protocols ensure that biological samples remain viable and
unaltered during transit.
Facilitating global collaboration: The ability to securely ship specimens worldwide enables researchers to work together on a broader scale.
Accelerating drug development: Specimens collected from different geographic areas can help to test the efficacy of potential cancer drugs in diverse patient populations.
Every aspect of our process is ultimately designed to provide patients with access to personalized and optimized therapies, potentially leading to improved survival rates, fewer side effects, and a better quality of life.
